Overview

Pharmacokinetics of Apixaban in Nephrotic Syndrome

Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
This study is to investigate the pharmacokinetics and pharmacodynamics of apixaban in nephrotic syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
North Carolina Translational and Clinical Sciences Institute
Treatments:
Apixaban